NAD agrees with most Prehistin supplement claims
This article was originally published in The Tan Sheet
Executive SummaryCobalis Corp. supports most print advertising claims that its Prehistin dietary supplement works by raising serum B12 levels and lowering serum levels of immunoglobulin E, which plays a role in allergy response, according to a recent National Advertising Division review. Supported claims included the product is an "all-natural formula," it is "free of side effects" and "has been shown to effectively regulate IgE levels in individuals while significantly increasing serum vitamin B12 levels." However, the watchdog group recommended the Irvine, Calif.-based advertiser discontinue the claim that the product works for "weeks after you stop taking it" and that it is "allergist recommended." The company agreed to comply with NAD's recommendations
You may also be interested in...
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.
The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.